ES2406391T3 - Inmunoterapia alérgeno-específica a través de la mucosa con dosificación inicial después de comenzar la estación de polen - Google Patents

Inmunoterapia alérgeno-específica a través de la mucosa con dosificación inicial después de comenzar la estación de polen Download PDF

Info

Publication number
ES2406391T3
ES2406391T3 ES09730293T ES09730293T ES2406391T3 ES 2406391 T3 ES2406391 T3 ES 2406391T3 ES 09730293 T ES09730293 T ES 09730293T ES 09730293 T ES09730293 T ES 09730293T ES 2406391 T3 ES2406391 T3 ES 2406391T3
Authority
ES
Spain
Prior art keywords
allergen
dosage form
administration
solid dosage
allergenic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09730293T
Other languages
English (en)
Spanish (es)
Inventor
Eike Gunther WÜSTENBERG
Eckhard-Carl Albrecht Puchert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ALK Abello AS
Original Assignee
ALK Abello AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39809974&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2406391(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ALK Abello AS filed Critical ALK Abello AS
Application granted granted Critical
Publication of ES2406391T3 publication Critical patent/ES2406391T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES09730293T 2008-04-11 2009-04-08 Inmunoterapia alérgeno-específica a través de la mucosa con dosificación inicial después de comenzar la estación de polen Active ES2406391T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US4440108P 2008-04-11 2008-04-11
DKPA200800533 2008-04-11
DK200800533 2008-04-11
US44401P 2008-04-11
PCT/EP2009/054186 WO2009124954A1 (en) 2008-04-11 2009-04-08 Mucosomal allergen-specific immunotherapy with initial dosing after start of pollen season

Publications (1)

Publication Number Publication Date
ES2406391T3 true ES2406391T3 (es) 2013-06-06

Family

ID=39809974

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09730293T Active ES2406391T3 (es) 2008-04-11 2009-04-08 Inmunoterapia alérgeno-específica a través de la mucosa con dosificación inicial después de comenzar la estación de polen

Country Status (12)

Country Link
US (2) US9248097B2 (enExample)
EP (1) EP2265285B1 (enExample)
JP (2) JP5618981B2 (enExample)
CN (1) CN102014954A (enExample)
AU (1) AU2009235490B2 (enExample)
BR (1) BRPI0911433A2 (enExample)
CA (1) CA2720455A1 (enExample)
DE (1) DE202008006598U1 (enExample)
EA (1) EA019202B1 (enExample)
ES (1) ES2406391T3 (enExample)
MX (1) MX2010011012A (enExample)
WO (1) WO2009124954A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004047793A1 (en) * 2002-11-26 2004-06-10 Alk-Abelló A/S Pharmaceutical allergen product
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
DE202008006598U1 (de) * 2008-04-11 2008-10-02 Alk-Abelló A/S Allergie-Impfstoff-Formulierung zur mucosalen Verabreichung
EP2627354B1 (en) * 2010-10-15 2015-07-15 ALK-Abelló A/S Suppression of a type 1 hypersensitivity immune response with an unrelated antigen
US20120100164A1 (en) 2010-10-15 2012-04-26 Alk-Abello A/S Suppression of a hypersensitivity immune response with unrelated antigen derived from allergen source material
WO2012148549A1 (en) 2011-02-25 2012-11-01 Benaroya Research Institute Detection of an immune response
JP2012240975A (ja) * 2011-05-20 2012-12-10 Nitto Denko Corp 医薬組成物及びゼリー状製剤
JP2012240978A (ja) * 2011-05-20 2012-12-10 Nitto Denko Corp 医薬組成物及びゼリー状製剤
SG10201605350UA (en) 2012-01-16 2016-08-30 Mckenna Elizabeth Compositions and Methods for the Treatment of Hepatic Diseases and Disorders
US12268718B2 (en) 2012-01-16 2025-04-08 Labyrinth Holdings Llc Control of cellular redox levels
KR102307248B1 (ko) 2012-08-21 2021-10-01 사노피 바이오테크놀로지 Il-4r 길항제의 투여에 의한 천식의 치료 또는 예방 방법
NZ630178A (en) 2012-09-07 2017-06-30 Regeneron Pharma Methods for treating atopic dermatitis by administering an il-4r antagonist
WO2014047588A1 (en) 2012-09-21 2014-03-27 Elizabeth Mckenna Naturally occurring cpg oligonucleotide compositions and therapeutic applications thereof
TWI755763B (zh) 2013-06-04 2022-02-21 美商再生元醫藥公司 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
TWI682781B (zh) 2013-07-11 2020-01-21 美商再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
KR20160120735A (ko) 2014-02-28 2016-10-18 리제너론 파아마슈티컬스, 인크. Ｉｌ-4ｒ 길항제의 투여에 의한 피부 감염의 치료 방법
CA2967602C (en) 2014-11-14 2024-09-24 Regeneron Pharmaceuticals, Inc. METHODS OF TREATMENT OF CHRONIC SINUSITIS WITH NASAL POLYPOSIS BY ADMINISTRATION OF AN IL-4R ANTAGONIST
US11771743B2 (en) 2016-09-01 2023-10-03 Regeneron Pharmaceuticals, Inc. Methods for preventing or treating allergy by administering an IL-4R antagonist
US10485844B2 (en) 2016-09-22 2019-11-26 Regeneron Pharmaceuticals, Inc. Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor
TWI857389B (zh) 2016-12-01 2024-10-01 美商再生元醫藥公司 治療發炎症狀的方法
WO2019028367A1 (en) 2017-08-04 2019-02-07 Regeneron Pharmaceuticals, Inc. METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES
EP4344706A3 (en) 2017-10-30 2024-05-22 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4r antagonist
CN120227453A (zh) 2018-05-13 2025-07-01 瑞泽恩制药公司 用于通过施用il-4r抑制剂治疗特应性皮炎的方法
KR20210143246A (ko) 2019-03-21 2021-11-26 리제너론 파아마슈티컬스, 인크. 알레르기 치료용 il-4/il-13 경로 억제제 및 형질 세포 절제의 병용
BR112022000740A2 (pt) 2019-07-16 2022-07-05 Sanofi Biotechnology Métodos para tratamento ou prevenção de asma por administração de um antagonista de il-4r
EP4010373A1 (en) 2019-08-05 2022-06-15 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r antagonist
KR20220042217A (ko) 2019-08-05 2022-04-04 리제너론 파아마슈티컬스, 인크. Il-4r 길항제를 투여함에 의해 알레르기를 치료하고 알레르겐-특이적 면역치료요법을 증진시키기 위한 방법
EP4513185A1 (en) * 2023-08-22 2025-02-26 Luxembourg Institute of Health (LIH) Early response biomarkers for allergen immunotherapy

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK137992D0 (da) 1992-11-13 1992-11-13 Alk Lab As Fremgangsmaade til paavisning af et immunologisk aktivt stof i en proeve under anvendelse af et maerkningsstof
JPH0959179A (ja) * 1995-08-28 1997-03-04 Japan Tobacco Inc スギ花粉症予防性を有する口腔衛生剤
DK1062341T3 (da) 1998-03-16 2008-11-03 Alk Abello As Muterede rekombinante allergener
FR2778244B1 (fr) 1998-04-30 2000-07-13 Univ Joseph Fourier Procede d'excitation d'une cavite optique pour la detection de gaz a l'etat de traces
DE60136653D1 (de) 2000-11-16 2009-01-02 Alk Abello As Mutante allergene
EP1504089A2 (en) 2002-05-16 2005-02-09 Alk Abell A/S Allergen mutants
WO2004047793A1 (en) * 2002-11-26 2004-06-10 Alk-Abelló A/S Pharmaceutical allergen product
WO2005077410A1 (en) 2004-02-06 2005-08-25 Greer Laboratories, Inc. Methods and compositions for dosing of allergens
BRPI0508078A (pt) * 2004-02-26 2007-07-17 Alk Abello As método para avaliar o potencial terapêutico de uma vacina para administração mucosa
US20060115499A1 (en) 2004-09-27 2006-06-01 Alk-Abello A/S Liquid allergy vaccine formulation for oromucosal administration
JP5628473B2 (ja) 2004-11-10 2014-11-19 アルク−アベッロ エイ／エスＡｌｋ−Ａｂｅｌｌｏ Ａ／Ｓ アレルギーワクチンの粘膜投与によるアレルギーの予防治療方法
DK1812059T3 (da) 2004-11-10 2010-09-13 Alk Abello As Fremgangsmåde til forebyggende behandling af allergi ved mukosaadministration af en allergivaccine
CN101098711A (zh) * 2005-01-07 2008-01-02 阿尔克-阿贝洛有限公司 通过口粘膜施用变态反应疫苗预防性治疗变态反应的方法
US20060210590A1 (en) * 2005-02-03 2006-09-21 Alk-Abello A/S Minor allergen control to increase safety of immunotherapy
AU2006299310A1 (en) 2005-10-04 2007-04-12 Alk-Abello A/S Solid vaccine formulation
EP1814516B1 (en) 2005-11-04 2012-12-26 Alk-Abelló A/S Use of a liquid allergy vaccine formulation for oromucosal administration
EP1974746B1 (en) * 2007-03-28 2012-01-11 Alk-Abelló A/S Use of an adjuvanted allergy vaccine formulation for parenteral administration
DE202007004567U1 (de) 2007-03-28 2007-10-11 Alk-Abelló A/S Verwendung einer adjuvierten Allergievakzinformulierung zur parenteralen Verabreichung
DE202008006598U1 (de) * 2008-04-11 2008-10-02 Alk-Abelló A/S Allergie-Impfstoff-Formulierung zur mucosalen Verabreichung

Also Published As

Publication number Publication date
JP2011516521A (ja) 2011-05-26
CN102014954A (zh) 2011-04-13
EP2265285B1 (en) 2013-03-20
EA019202B1 (ru) 2014-01-30
US9248097B2 (en) 2016-02-02
DE202008006598U1 (de) 2008-10-02
WO2009124954A1 (en) 2009-10-15
JP2015013891A (ja) 2015-01-22
EP2265285A1 (en) 2010-12-29
CA2720455A1 (en) 2009-10-15
US20110142934A1 (en) 2011-06-16
US20140127298A1 (en) 2014-05-08
HK1147946A1 (en) 2011-08-26
EA201071182A1 (ru) 2011-06-30
AU2009235490A1 (en) 2009-10-15
BRPI0911433A2 (pt) 2016-07-26
JP5618981B2 (ja) 2014-11-05
AU2009235490B2 (en) 2013-10-24
MX2010011012A (es) 2010-11-12

Similar Documents

Publication Publication Date Title
ES2406391T3 (es) Inmunoterapia alérgeno-específica a través de la mucosa con dosificación inicial después de comenzar la estación de polen
US10471008B2 (en) Allergen dosage form
HK1200019A1 (en) Use of a liquid allergy vaccine formulation for oromucosal administration
ES2370043T3 (es) Uso de una formulación de vacuna de la alergia coadyuvada para administración subcutánea.
ES2399914T3 (es) Uso de una formulación líquida de vacuna contra la alergia para administración oromucosa
HK1147946B (en) Mucosomal allergen-specific immunotherapy with initial dosing after start of pollen season
HK1110773B (en) Use of a liquid allergy vaccine formulation for oromucosal administration